GE HealthCare to Buy Sofie for Nearly $1 Billion to Grow Medical-Imaging Business -- WSJ

Dow Jones2026/10/05 11:30

By Peter Loftus GE HealthCare Technologies is expected to announce Monday a $945 million cash purchase of a manufacturer of radioactive substances used in medical-imaging procedures. The deal marks a continued push by medical-equipment maker GE HealthCare into the growing market for radiopharmaceuticals, which have uses for both diagnosing and treating diseases including cancer, heart disease and Alzheimer's. Drugmakers such as Novartis and other devicemakers have been investing in the segment. In August, Curium struck a deal to acquire Lantheus Holdings for an initial $6.7 billion in a consolidation of two radiopharma companies. The details GE HealthCare has agreed to acquire Sofie Biosciences from private-equity firm Trilantic North America, the company said. Sofie makes tracer agents that are injected into patients during PET scans, which help create images of tumors or other hidden parts of the body. Sofie, based in Dulles, Va., operates a network of specialized pharmacies that distribute the tracers used in PET scans. The deal will include the U.S. rights to FAPI-74, a tracer that is in late-stage clinical trials for detecting cancers that GE HealthCare thinks can be a big seller if it is cleared by regulators. GE HealthCare already holds rights to the tracer outside the U.S. The context GE HealthCare's pharmaceutical-diagnostics business, which includes the injections used in PET scans, had $2.9 billion in revenue last year. Revenue from the division rose about 15% in the second quarter and comprises about 16% of the company's total. Chief Exeuctive Peter Arduini has identified radiopharmaceuticals as a key focus for the company, which has been experiencing slower growth in other parts of its business. "It's the fastest-growing segment of our business today, radiopharmaceuticals," said Kevin O'Neill, head of GE HealthCare's pharmaceutical-diagnostics business. "This is why it's important to invest in this segment." GE HealthCare sees the deal closing in the first half of 2027 and expects it to add to revenu

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Middle Eastern oil flow restored to about 80% of pre-war levels; Shell CEO Sawan says energy security is the cornerstone of national security.

According to reports, Shell (SHEL.US) CEO Wael Sawan said on Tuesday that Middle East oil flows have recovered to about 80% of pre-war levels.

智通财经•2026/10/07 06:06

High volatility + live trading | The holiday ends, and a turning point arrives! BTC is compressed at high levels, ETH breaks out first—beware of cascading liquidations

AiCoin•2026/10/07 06:05

BUZZ-Australia's Kelsian shares rise as asset sale triggers Morningstar's cautious optimism

Latest developments on October 7th – Kelsian Group (KLS.AX) shares briefly rose 1% to A$3.93 before narrowing gains to 0.3% by midday in Sydney. Morningstar holds a positive view on the transport operator’s recently announced A$150 million (US$104.76 million) sale of travel assets in mid-September. The investment research firm noted that this divestment relieves the transportation and travel operator from reliance on discretionary-spending businesses such as resorts, cruises, and tours. It also stated that the sale enables management to focus more on core operations and moderately reduces capital intensity. However, Morningstar pointed out that the sale means profits from the marine segment will still be "discretionary in nature." It added that the sale will leave the company’s earnings mainly dependent on its US interstate coach business, which is characterized by short-term contracts without cost-adjustment mechanisms and serves highly volatile sectors such as technology, oil, and gas. Year to date, the share price is down 8.2%. (US$1 = A$1.4318) (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be inaccurate or may not completely reflect the required context; Reuters does not guarantee the accuracy of translated texts, which are provided solely for reader convenience. Reuters is not responsible for any harm or loss arising from the use of automatic translation.)

路透社•2026/10/07 04:36

JPMorgan raises Gilead Sciences' target price to $170.

格隆汇•2026/10/07 04:27